These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

37 related articles for article (PubMed ID: 23180531)

  • 1. [Genetic factors influencing efficacy of clopidogrel treatment].
    Karaźniewicz-Łada M; Danielak D; Główka F
    Kardiol Pol; 2012; 70(11):1177-81. PubMed ID: 23180531
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study.
    Fontana P; James R; Barazer I; Berdagué P; Schved JF; Rebsamen M; Vuilleumier N; Reny JL
    J Thromb Haemost; 2011 Aug; 9(8):1664-6. PubMed ID: 21692977
    [No Abstract]   [Full Text] [Related]  

  • 3. Genetic determinants of on-clopidogrel high platelet reactivity.
    Campo G; Miccoli M; Tebaldi M; Marchesini J; Fileti L; Monti M; Valgimigli M; Ferrari R
    Platelets; 2011; 22(6):399-407. PubMed ID: 21627411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors that contribute to clopidogrel resistance in cardiovascular disease patients: environmental and genetic approach.
    Al-Azzam SI; Alzoubi KH; Khabour OF; Nusair MB; Al-Hadidi H; Awidi A; Saleh A
    Int J Clin Pharmacol Ther; 2013 Mar; 51(3):179-86. PubMed ID: 23357840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Besides CYP2C19, PON1 genetic variant influences post-clopidogrel platelet reactivity in Chinese patients.
    Wu H; Qian J; Xu J; Sun A; Sun W; Wang Q; Ge J
    Int J Cardiol; 2013 Apr; 165(1):204-6. PubMed ID: 22974728
    [No Abstract]   [Full Text] [Related]  

  • 6. Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome.
    Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Romero-Barra M; Camoin L; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
    Thromb Haemost; 2007 Feb; 97(2):212-7. PubMed ID: 17264949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P-450 polymorphisms and response to clopidogrel.
    Miao J; Liu R; Li Z
    N Engl J Med; 2009 May; 360(21):2250-1. PubMed ID: 19469033
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.
    Frere C; Cuisset T; Morange PE; Quilici J; Camoin-Jau L; Saut N; Faille D; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
    Am J Cardiol; 2008 Apr; 101(8):1088-93. PubMed ID: 18394438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
    Maree AO; Fitzgerald DJ
    Circulation; 2007 Apr; 115(16):2196-207. PubMed ID: 17452618
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of paraoxonase-1 in CYP2C19 loss-of-function carriers.
    Daali Y; Reny JL; Fontana P
    Thromb Res; 2014 Mar; 133(3):519. PubMed ID: 24439677
    [No Abstract]   [Full Text] [Related]  

  • 11. Clopidogrel dosing based on genotype.
    Alexopoulos D; Xanthopoulou I
    JAMA; 2012 Mar; 307(10):1024; author reply 1024-5. PubMed ID: 22416093
    [No Abstract]   [Full Text] [Related]  

  • 12. Smoking, atherothrombosis and clopidogrel.
    Warner TD; Paul-Clark M; Mitchell JA
    Heart; 2012 Jul; 98(13):963-4. PubMed ID: 22668863
    [No Abstract]   [Full Text] [Related]  

  • 13. Contemporary issues on clopidogrel therapy: a critical appraisal.
    Capodanno D; Angiolillo DJ
    Intern Emerg Med; 2009 Jun; 4(3):195-8. PubMed ID: 19333714
    [No Abstract]   [Full Text] [Related]  

  • 14. Clopidogrel hyporesponsiveness: are we all the same?
    Tan DS
    Am J Health Syst Pharm; 2011 Sep; 68(17):1578-80; author reply 1580. PubMed ID: 21856801
    [No Abstract]   [Full Text] [Related]  

  • 15. Paraoxonase-1 and clopidogrel efficacy.
    Camps J; Joven J; Mackness B; Mackness M; Tawfik D; Draganov D; Costa LG; Paragh G; Seres I; Horke S; James R; Hernández A; Reddy S; Shih D; Navab M; Rochu D; Aviram M
    Nat Med; 2011 Sep; 17(9):1041-2; author reply 1042-4. PubMed ID: 21900915
    [No Abstract]   [Full Text] [Related]  

  • 16. Paraoxonase-1 and clopidogrel efficacy.
    Dansette PM; Rosi J; Bertho G; Mansuy D
    Nat Med; 2011 Sep; 17(9):1040-1; author reply 1042-4. PubMed ID: 21900914
    [No Abstract]   [Full Text] [Related]  

  • 17. Paraoxonase-1 and clopidogrel efficacy.
    Cuisset T; Morange PE; Quilici J; Bonnet JL; Gachet C; Alessi MC
    Nat Med; 2011 Sep; 17(9):1039; author reply 1042-4. PubMed ID: 21900913
    [No Abstract]   [Full Text] [Related]  

  • 18. Unveiling the mysteries of clopidogrel metabolism and efficacy.
    Bonello L; Bonello N; Grosdidier C; Camoin-Jau L
    Clin Pharmacol Ther; 2011 Dec; 90(6):774-6. PubMed ID: 22089343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revival of PFA-100--how far is it useful for the monitoring of ADP receptor antagonists?
    Golanski J; Syska K; Watala C
    Thromb Haemost; 2013 Mar; 109(3):564-5. PubMed ID: 23348862
    [No Abstract]   [Full Text] [Related]  

  • 20. Paraoxonase 1 Q192R variant and clopidogrel efficacy: fact or fiction?
    Lewis JP; Shuldiner AR
    Circ Cardiovasc Genet; 2012 Apr; 5(2):153-5. PubMed ID: 22511706
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.